Stahl Neil

Stahl Neil is listed in filings as EVP Research and Development at Regeneron Pharmaceuticals Inc. This profile follows SEC Form 4 activity through Dec 18, 2024, including 3 public disclosures. Recent filings connect the profile to Regeneron Pharmaceuticals Inc (REGN). The current snapshot covers public activity from Aug 14, 2024 to Dec 18, 2024. Reported amounts are shown as $222.2K to $366.7K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.